Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Waalkes, Sandra ^a   Atschekzei, Faranaz ^a   Kramer, Mario W ^a   Hennenlotter, Jörg ^b   Vetter, Gesa ^a   Becker, Jan U ^a   Stenzl, Arnulf ^b   Merseburger, Axel S ^a   Schrader, Andres J ^c   Kuczyk, Markus A ^a   Serth, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; FIBRONECTIN 1; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; ONCOCYTOMA; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; CANCER STAGING; COMPARATIVE STUDY; DISEASE COURSE; GENETICS; KIDNEY; KIDNEY TUMOR; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADENOMA, OXYPHILIC; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; FIBRONECTINS; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77956821617     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-503     Document Type: Article

References (28)

1. Schrader AJ, Rustemeier J, Rustemeier JC, Timmesfeld N, Varga Z, Hegele A, Olbert PJ, Hofmann R. Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol 2009, 135:1693-1699. 10.1007/s00432-009-0616-2, 19543914.
2. Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R. [Gender-specific characteristics and survival of renal cell carcinoma]. Urologe A 2008, 47(1182):1184-1186.
3. Wilson CB, Leopard J, Cheresh DA, Nakamura RM. Extracellular matrix and integrin composition of the normal bladder wall. World J Urol 1996, 14(Suppl 1):S30-37.
4. Akiyama SK, Olden K, Yamada KM. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 1995, 14:173-189. 10.1007/BF00690290, 8548867.
5. Warawdekar UM, Zingde SM, Iyer KS, Jagannath P, Mehta AR, Mehta NG. Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients. Clin Chim Acta 2006, 372:83-93. 10.1016/j.cca.2006.03.023, 16730689.
6. Haglund C, Ylatupa S, Mertaniemi P, Partanen P. Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA. Br J Cancer 1997, 76:777-783. 2228036, 9310245.
7. Torbenson M, Wang J, Choti M, Ashfaq R, Maitra A, Wilentz RE, Boitnott J. Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol 2002, 15:826-830. 10.1097/01.MP.0000024257.83046.7C, 12181267.
8. Ylatupa S, Haglund C, Mertaniemi P, Vahtera E, Partanen P. Cellular fibronectin in serum and plasma: a potential new tumour marker?. Br J Cancer 1995, 71:578-582. 2033647, 7880741.
9. Cho J, Mosher DF. Role of fibronectin assembly in platelet thrombus formation. J Thromb Haemost 2006, 4:1461-1469. 10.1111/j.1538-7836.2006.01943.x, 16839338.
10. Mosher DF. Plasma fibronectin concentration: a risk factor for arterial thrombosis?. Arterioscler Thromb Vasc Biol 2006, 26:1193-1195. 10.1161/01.ATV.0000223342.15969.7a, 16709950.
11. Orem C, Celik S, Orem A, Calapoglu M, Erdol C. Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus. Thromb Res 2002, 105:37-41. 10.1016/S0049-3848(01)00414-5, 11864705.
12. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80(5):992-993. 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q, 9307205.
13. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. The American journal of surgical pathology 1982, 6(7):655-663. 10.1097/00000478-198210000-00007, 7180965.
14. Stenzl A, deKernion JB. Pathology, biology, and clinical staging of renal cell carcinoma. Seminars in oncology 1989, 16(1 Suppl 1):3-11.
15. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108. 10.1038/nprot.2008.73, 18546601.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
17. Kampstra P. Beanplot: A Boxplot Alternative for Visual Comparison of Distributions. 2008, , http://www.cs.vu.nl/~pkampst/
18. de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999, 13:266-274. 10.1038/sj.leu.2401275, 10025901.
19. Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Elomaa I, Kallioniemi A, Kallioniemi OP, Knuutila S. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet 2000, 123:128-132. 10.1016/S0165-4608(00)00319-8, 11156738.
20. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000, 60:6617-6622.
21. Chen M, Marinkovich MP, Jones JC, O'Toole EA, Li YY, Woodley DT. NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats. J Invest Dermatol 1999, 112:177-183. 10.1046/j.1523-1747.1999.00491.x, 9989793.
22. Takayasu H, Horie H, Hiyama E, Matsunaga T, Hayashi Y, Watanabe Y, Suita S, Kaneko M, Sasaki F, Hashizume K, et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res 2001, 7:901-908.
23. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 2001, 128:1-6. 10.1016/S0165-4608(01)00386-7, 11454421.
24. Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Timmesfeld N, Varga Z, Hofmann R. Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol 2009, 135:799-805. 10.1007/s00432-008-0515-y, 19023595.
25. Brenner W, Gross S, Steinbach F, Horn S, Hohenfellner R, Thuroff JW. Differential inhibition of renal cancer cell invasion mediated by fibronectin, collagen IV and laminin. Cancer Lett 2000, 155:199-205. 10.1016/S0304-3835(00)00429-8, 10822136.
26. Lohi J, Tani T, Leivo I, Linnala A, Kangas L, Burgeson RE, Lehto VP, Virtanen I. Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice. Int J Cancer 1996, 68:364-371. 10.1002/(SICI)1097-0215(19961104)68:3<364::AID-IJC15>3.0.CO;2-8, 8903479.
27. Murata J, Saiki I, Yoneda J, Azuma I. Differences in chemotaxis to fibronectin in weakly and highly metastatic tumor cells. Jpn J Cancer Res 1992, 83:1327-1333.
28. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005, 23:2763-2771. 10.1200/JCO.2005.07.055, 15837991.